Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04562116 · ClinicalTrials.gov registry record · Phase 2
A Study to Assess the Effects of Nemolizumab on Cytochrome P450 Substrates in Participants With Moderate-to-Severe Atopic Dermatitis
A Phase 2 study, sponsored by Galderma R&D.
- Completed
- Registry status
- Phase 2
- Development phase
- 17
- Enrollment target
NCT04562116 is a Phase 2 study that has completed, run by Galderma R&D. The registered enrollment target is 17 participants.
The verdict
NCT04562116, a Phase 2 study, has completed, sponsored by Galderma R&D.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 17 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the effect of nemolizumab (CD14152) on the pharmacokinetics (PK) of a drug "cocktail" representative of CYP450 (CYP1A2, CYP2C9, CYP2C19, CYP2D6 and CYP3A4/5 sensitive index substrates) in adult participants with moderate to- severe atopic dermatitis (AD).
Interventions
- DRUG Nemolizumab
- DRUG CYP 450 Substrates
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17 participants |
| Start Date | 2021-12-08 |
| Est. Completion | 2023-06-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04562116
The ClinicalTrials.gov registry entry for NCT04562116 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 17 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Galderma R&D, which has 158 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Nemolizumab is the first listed.
NCT04562116 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04562116 about?
NCT04562116 is a clinical study titled "A Study to Assess the Effects of Nemolizumab on Cytochrome P450 Substrates in Participants With Moderate-to-Severe Atopic Dermatitis". The purpose of this study is to evaluate the effect of nemolizumab (CD14152) on the pharmacokinetics (PK) of a drug "cocktail" representative of CYP450 (CYP1A2, CYP2C9, CYP2C19, CYP2D6 and CYP3A4/5 sensitive index substrates) in adult participants with moderate to- severe atopic dermatitis (AD).
What is the current status of trial NCT04562116?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 17 participants. The study started on 2021-12-08. Estimated completion is 2023-06-07.
What interventions are being tested in trial NCT04562116?
The interventions under investigation include: Nemolizumab (DRUG), CYP 450 Substrates (DRUG).
Who is sponsoring clinical trial NCT04562116?
This trial is sponsored by Galderma R&D, which has 158 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.